2022-05-13T12:57:13-05:00 2021-06-30 366055558 GRANT THORNTON LLP 200 S ORANGE AVENUE SUITE 2050 ORLANDO FL 32801 990 2020-07-01 592451713 H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE INC HLEE 8137454673 12902 MAGNOLIA DRIVE TAMPA FL 33612 YVETTE M LYONS TREMONTI EVP/CFAO 8137457862 2022-05-13 1 YVETTE LYONS TREMONTI 999009999 MICHELE N MELCHIOR P00488037 4074815100 2 AAL1 IAL1 2020 2022-09-23 18:48:47Z DR PATRICK HWU 12902 MAGNOLIA DRIVE TAMPA FL 33612 404020517 0 X WWW.MOFFITT.ORG X 1984 FL TO PROMOTE AND SUPPORT THROUGH RESEARCH, MANAGEMENT AND OTHER MEANS OF SUPPORT. 24 24 2632 77 20331164 14952638 180471501 175685146 21623423 29520513 -1449863 -32126490 2564420 2898335 203209481 175977504 505564 402347 0 0 140826199 155422536 0 0 0 96534299 101704706 237866062 257529589 -34656581 -81552085 1582286412 1835186775 879938884 910000881 702347528 925185894 X SEE SCHEDULE OTO PROMOTE AND SUPPORT H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE LIFETIME CANCER SCREENING CENTER, AND H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE FOUNDATION THROUGH RESEARCH, MANAGEMENT, AND OTHER MEANS OF SUPPORT. 0 0 172245218 402347 28299989 THE H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. IS ARECOGNIZED LEADER IN FOCUSED, INNOVATIVE CANCER RESEARCH, A MAJORREGIONAL ONCOLOGY REFERRAL CENTER, AND A NATIONAL CANCER INSTITUTE DESIGNATED COMPREHENSIVE CANCER CENTER.SEE SCHEDULE O FOR CONTINUATIONBASED ON ITS SINGULAR MISSION - TO CONTRIBUTE TO THE PREVENTION ANDCURE OF CANCER - THE CANCER CENTER'S RESEARCH ACTIVITIES RELATEPRIMARILY TO THE AREAS OF BASIC SCIENCE, CANCER PREVENTION AND CONTROL, TRANSLATIONAL SCIENCE, PRE-CLINICAL AND CLINICAL INVESTIGATIONS, AND PROVIDING MANAGEMENT AND OTHER SUPPORT SERVICES AS THE SOLE CORPORATE MEMBER AND PARENT FOR THE FOLLOWING SUBSIDIARY CORPORATIONS:H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. (THE HOSPITAL) WHICH PROVIDES MEDICAL AND HOSPITAL CARE, MEDICAL EDUCATION AND TRAINING, AND CLINICAL (PATIENT-RELATED) RESEARCH IN MAINTAINING HEALTH, AND PREVENTING, DETECTING, AND TREATING CANCER;H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE LIFETIME CANCERSCREENING CENTER, INC. (MOFFITT MEDICAL GROUP) WHICH EMPLOYS ANDMANAGES PHYSICIANS AND OTHER MEDICAL PROFESSIONALS WHO STAFF THEHOSPITAL, AND PROVIDE CLINICAL RESEARCH SERVICES TO THE CANCER CENTER; AND H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE FOUNDATION, INC. (THE FOUNDATION) WHICH IS THE PRINCIPAL FUND-RAISING ORGANIZATION FOR THE CANCER CENTER AND ITS SUBSIDIARIES.THE CANCER CENTER'S MULTIDISCIPLINARY CLINICAL PROGRAM STRUCTURE AND OPEN LABORATORY ARCHITECTURE PROVIDE AN ENVIRONMENT CONDUCIVE FOR TRAINING FUTURE SCIENTIFIC AND CLINICAL LEADERS IN ONCOLOGY, AND REFLECT THE CANCER CENTER'S COMMITMENT TO COLLABORATION IN ALL ASPECTS OF CANCER RESEARCH. 172245218 1 1 0 1 0 0 0 0 0 0 1 0 0 1 1 0 0 1 0 0 0 0 0 0 0 0 0 1 0 1 1 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 1 1 1 0 0 1 315 0 1 2632 1 1 1 0 0 0 0 0 0 0 0 0 1 0 X 24 24 1 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 1 1 1 X YVETTE M LYONS TREMONTI 8137457862 12902 MAGNOLIA DR TAMPA FL 33612 BENJAMIN H HILL III ESQ DIRECTOR, SECRETARY/TREASURER 1.00 1.00 X X 0 0 0 BETH A HOUGHTON DIRECTOR, VICE CHAIR 1.00 1.00 X X 0 0 0 TIMOTHY J ADAMS DIRECTOR, CHAIR 1.00 2.00 X X 0 0 0 ALAN LEVINE DIRECTOR 1.00 0.00 X 0 0 0 ALLISON ADAMS DIRECTOR 1.00 0.00 X 0 0 0 ANGELA BIEVER DIRECTOR 1.00 0.00 X 0 0 0 CARLOS ALFONSO DIRECTOR 1.00 0.00 X 0 0 0 CECELIA FERMAN DIRECTOR 1.00 0.00 X 0 0 0 EDWARD C DROSTE DIRECTOR 1.00 1.00 X 0 0 0 EDWARD DEBARTOLO DIRECTOR 1.00 0.00 X 0 0 0 FRANCISCO SANCHEZ DIRECTOR 1.00 0.00 X 0 0 0 GEOFFREY M DUYK PHD MD DIRECTOR 1.00 1.00 X 0 0 0 JOHN RAMIL DIRECTOR 1.00 0.00 X 0 0 0 JOHN TOMLIN DIRECTOR 1.00 0.00 X 0 0 0 JOSEPH CABALLERO DIRECTOR 1.00 2.00 X 0 0 0 LIZ SMITH DIRECTOR 1.00 0.00 X 0 0 0 PAMELA STEWART DIRECTOR 1.00 0.00 X 0 0 0 REGINALD GOINS DIRECTOR 1.00 1.00 X 0 0 0 STEVEN CURRALL DIRECTOR 1.00 0.00 X 0 0 0 THE HON CARL CARPENTER DIRECTOR 1.00 0.00 X 0 0 0 THE HON H LEE MOFFITT ESQ DIRECTOR 1.00 2.00 X 0 0 0 THE HON JAMES T HARGRETT ESQ DIRECTOR 1.00 0.00 X 0 0 0 THE HON JOHN A GRANT ESQ DIRECTOR 1.00 0.00 X 0 0 0 VALERIE GODDARD DIRECTOR 1.00 1.00 X 0 0 0 JOHN A KOLOSKY EVP COO TO 1/4/2021 24.00 32.00 X 1028625 0 760536 YVETTE M LYONS TREMONTI EVP-CFAO & ASST TREASURER 22.00 36.00 X 1047333 0 362800 G DOUGLAS LETSON EVP-PIC 18.00 37.00 X 0 1011339 199081 L DAVID DE LA PARTE EVP GEN COUNS & ASST SEC 22.00 36.00 X 927786 0 282255 JOHN CLEVELAND EVP-CENTER DIRECTOR 55.00 1.00 X 811269 0 182255 JONATHAN ZAGER CHIEF ACADEMIC OFFICER 15.00 40.00 X 0 694707 221896 WJ WILSON VP GOVT RELATIONS 55.00 0.00 X 431621 0 334185 DANA E ROLLISON VP CHIEF DATA OFFICER 55.00 0.00 X 497628 0 213456 B LEE GREEN VP DIVERSITY, PR & STRAT COMM 55.00 0.00 X 487171 0 194430 EDMONDO ROBINSON SVP CHIEF DIGITAL INNOV OFFICER 55.00 1.00 X 640795 0 36850 BRIAN SPRINGER VP RESEARCH ADMINISTRATION 55.00 0.00 X 533935 0 128675 DIANE HAMMON VP CHIEF STRATEGY OFFICER 55.00 0.00 X 506511 0 144932 JOANNA WEISS VP FINANCE 30.00 25.00 X 487230 0 137334 MARIANA BUGALLO-MUROS VP CHIEF HR OFFICER 55.00 0.00 X 536011 0 56755 CHARLES FLETCHER VP DEPUTY GENERAL COUNSEL 55.00 0.00 X 405492 0 99570 DONALD FUTRELL VP PLAN, DESIGN & CONS 55.00 0.00 X 444242 0 54007 ROGER B BRADLEY VP FAC & SUP SVCS TO 10/15/2020 55.00 0.00 X 325620 9187 29198 ELIZABETH LINDSAY-WOOD VP-CIO 55.00 0.00 X 292610 0 2208 PATRICK HWU PRES/CEO AS OF 11/10/2020 30.00 26.00 X 219210 0 88 HENRY REYES VP-PARTNERSHIP DEVELOPMENT 25.00 30.00 X 195717 0 12054 TERRENCE WRIGHT VP-FAC & SUP SVCS AS OF 3/29/2021 35.00 20.00 X 0 0 0 SANTOSH MOHAN VP-DIGITAL AS OF 3/29/2021 55.00 0.00 X 0 0 0 JAMES J MULAY ACD TRANSLATIONAL RSCH 50.00 2.00 X 734523 0 45395 ANNA GIULIANO DIRECTOR CENTER OF EXCELLENCE 50.00 0.00 X 429467 0 240637 SUSAN VADAPARAMPIL ACD COMMUNITY OUTREACH & ENGAGEMENT 50.00 0.00 X 452860 0 161515 SHELLEY TWOROGER ACD POPULATION SCIENCE 50.00 0.00 X 452506 0 81984 RANDA M PERKINS CHIEF MEDICAL INFO OFFICER 50.00 0.00 X 471561 0 59695 LYNN MOSCINSKI FRM CHIEF ACADEMIC OFFICER TO 6/28/2019 0.00 50.00 X 0 633923 186912 ALAN F LIST FRM PRES/CEO TO 2/3/2020 0.00 0.00 X 506647 0 29264 SURESH D SERAPHIN FRM VP STRAT ALLIANCE & NETWK TO 5/15/2020 0.00 0.00 X 112221 0 242 THOMAS A SELLERS FRM EVP CNT DIR, DIR-MRI TO 2/3/2020 0.00 0.00 X 248684 0 -145572 13227275 2349156 4112637 398 1 1 0 BARR & BARR INC 460 W 34TH ST FL 10 NEW YORK NY 10001 PROFESSIONAL SERVICES 20806514 BIRDSALL VOSS & ASSOCIATES 250 W COVENTRY COURT STE 300 MILWAUKEE WI 53217 MARKETING SERVICES 7315269 WILLIS TOWER WATSON 3407 W DR MARTIN LUTHER KING JR BLV TAMPA FL 33607 PROFESSIONAL SERVICES 3240755 SHUMAKER LOOP & KENDRICK LLP 101 E KENNEDY BLVD STE 2800 TAMPA FL 33602 LEGAL SERVICES 2331110 MODUS DIRECT LLC 1343 MAIN ST STE 600 SARASOTA FL 34236 MARKETING SERVICES 2117600 85 22125241 96536028 57023877 946452 175685146 CELL THERAPY PRODUCTS 541700 15683416 1043931 14639485 MANAGEMENT SERVICES 541610 7889383 2352110 5537273 CORE LAB REVENUE 541900 4564041 4564041 M2GEN SERVICE REVENUE 541900 1074210 1074210 ONCOBAY SERVICE REVENUE 541900 146314 146314 163149 163149 29520513 5479133 5479133 4426 4426 156552 7800 148752 148752 148752 158055635 32369529 174080903 53954310 -16025268 -21584781 -37610049 -37610049 LICENSE FEES 900099 1307836 1307836 PARKING 900099 757341 5001 752340 UNCLAIMED PROPERTY 900099 216286 216286 468120 653 467467 2749583 175977504 9348181 20331164 -29386987 X 402347 402347 11786643 9685438 2101205 120915737 81264932 39650805 5790217 4002149 1788068 9167126 7057816 2109310 7762813 5188300 2574513 2303936 2303936 67220 67220 142376 142376 1014789 1014789 35072533 17099976 17972557 2466575 31136 2435439 22409283 16886572 5522711 6844949 6844949 4701065 309020 4392045 690645 25777 664868 2153873 2153873 11878296 11878296 204899 204899 ALLOCATION OF INTERCOMP 0 23404824 -23404824 CORE LAB EXPENSES 3218163 3218163 0 INCOME TAX EXPENSE 2774324 0 2774324 ECONOMIC DEVELOPMENT - 1927290 1927290 0 3834490 1741478 2093012 257529589 172245218 85284371 0 245490296 345309770 496265103 418528504 20089365 24264487 13392531 14604600 1118181259 510116988 494139096 608064271 222114858 289310756 500100 15200000 90295064 119904387 1582286412 1835186775 144793959 185677847 2512108 1912822 702490577 686624709 30142241 35785503 879938884 910000881 X 635201170 846915817 67146358 78270077 702347528 925185894 1582286412 1835186775 X -81552085 82172266 222218185 X 0 1 X 1 1 1 X 142592916 151923266 161127950 180471501 175685146 811800779 142592916 151923266 161127950 180471501 175685146 811800779 811800779 2862859 4551933 6650393 6162666 5483559 25711410 2586085 4703817 6715669 10846860 14952638 39805069 2506415 27639537 4037784 2314119 2743929 39241784 916559042 33578218 0.88570 0.89690 X SCHEDULE A, PART II, LINE 10, EXPLANATION OF OTHER INCOME: LICENSE FEES - 2016 AMOUNT: $ 546,788. 2017 AMOUNT: $ 26,131,592. 2018 AMOUNT: $ 2,496,454. 2019 AMOUNT: $ 291,471. 2020 AMOUNT: $ 1,307,836. PARKING - 2016 AMOUNT: $ 1,004,190. 2017 AMOUNT: $ 916,930. 2018 AMOUNT: $ 950,775. 2019 AMOUNT: $ 889,946. 2020 AMOUNT: $ 752,340. EYE INSTITUTE REIMBURSEMENT - 2016 AMOUNT: $ 146,619. 2017 AMOUNT: $ 128,217. 2018 AMOUNT: $ 36,832. LEASES - 2016 AMOUNT: $ 21,551. 2017 AMOUNT: $ 69,570. 2018 AMOUNT: $ 66,885. 2019 AMOUNT: $ 32,016. 2020 AMOUNT: $ 76,012. STAFF RETAIL SERVICES - 2016 AMOUNT: $ 51,364. 2017 AMOUNT: $ 59,077. 2018 AMOUNT: $ 45,748. 2019 AMOUNT: $ 33,888. 2020 AMOUNT: $ 23,681. SETTLEMENT - 2016 AMOUNT: $ 410,360. 2017 AMOUNT: $ 204,624. SUPPORT ACCOUNTS - 2016 AMOUNT: $ 232,370. 2017 AMOUNT: $ 15,078. 2018 AMOUNT: $ 179,614. 2019 AMOUNT: $ 758,853. REBATES/REFUNDS - 2016 AMOUNT: $ 85,728. 2017 AMOUNT: $ 83,127. 2018 AMOUNT: $ 247,557. 2019 AMOUNT: $ 171,326. 2020 AMOUNT: $ 161,862. MISC - 2016 AMOUNT: $ 7,445. 2017 AMOUNT: $ 31,322. 2018 AMOUNT: $ 13,919. 2019 AMOUNT: $ 11,786. 2020 AMOUNT: $ 21,788. REIMBURSEMENT OF EXPENSES - 2019 AMOUNT: $ 55,568. 2020 AMOUNT: $ 116,640. PATENT EXPENSE REIMBURSEMENT - 2019 AMOUNT: $ 69,265. 2020 AMOUNT: $ 67,484. UNCLAIMED PROPERTY - 2020 AMOUNT: $ 216,286. RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 1 1 0 1 4204 1 11266 0 1 207174 1 8778 1 11233 242655 0 PART II-B, LINE 1: THE H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. AND ITS THREE NON-PROFIT SUBSIDIARY CORPORATIONS ("CORPORATION") WERE CREATED TO GOVERN AND OPERATE THE H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE ("INSTITUTE") PURSUANT TO SECTION 1004.43, FLORIDA STATUTES. AMONG OTHER THINGS, SECTION 1004.43, FLORIDA STATUTES PROVIDES: (1) THAT THE CORPORATION SHALL ENTER INTO AN AGREEMENT WITH THE STATE BOARD OF EDUCATION FOR THE UTILIZATION OF FACILITIES ON THE CAMPUS OF THE UNIVERSITY OF SOUTH FLORIDA; (2) THAT THE CORPORATION SUBMIT ANNUAL POST AUDITS OF ITS FINANCIAL ACCOUNTS TO THE AUDITOR GENERAL OF THE STATE OF FLORIDA AND THE BOARD OF GOVERNORS FOR THEIR REVIEW; AND (3) THAT THE CORPORATION'S CEO REPORT TO THE BOARD OF GOVERNORS OR ITS DESIGNEE AND PROVIDE COPIES OF THE INSTITUTE'S ANNUAL REPORT TO THE GOVERNOR OF THE STATE OF FLORIDA, THE CABINET, THE PRESIDENT OF THE SENATE, THE SPEAKER OF THE HOUSE AND THE CHAIR OF THE BOARD OF GOVERNORS. ALTHOUGH THE CORPORATION IS A PRIVATE ENTITY, IT IS NONETHELESS SUBJECT TO THE STATE OF FLORIDA'S PUBLIC RECORDS AND THE PUBLIC MEETINGS LAWS. THE CORPORATION ALSO RELIES ON ANNUAL APPROPRIATIONS BY THE LEGISLATURE OF THE STATE OF FLORIDA AND GRANTS FROM VARIOUS LOCAL, STATE AND FEDERAL AGENCIES FOR OPERATION AND MAINTENANCE OF ITS FACILITIES AND FOR SPECIFIC RESEARCH AND CLINICAL PROGRAMS. FOR THESE REASONS, THE CORPORATION FROM TIME TO TIME ENGAGES LOBBYISTS AND OTHER CONSULTANTS; (1) TO ASSIST IT IN COMPLYING WITH ITS REPORTING REQUIREMENTS TO THE STATE OF FLORIDA UNDER SECTION 1004.43, FLORIDA STATUTES; (2) TO MONITOR LEGISLATIVE AND EXECUTIVE BRANCH ACTION AT LOCAL, STATE AND FEDERAL LEVELS OF GOVERNMENT WHICH IMPACT ITS OPERATION AND THE FULFILLMENT OF ITS MISSION; AND (3) TO INFLUENCE LEGISLATION IN FURTHERANCE OF ITS MISSION IN THE AREAS OF CANCER RESEARCH AND TREATMENT, THE TEACHING AND TRAINING OF HEALTH CARE PROFESSIONALS AND COMMUNITY EDUCATION AND OUTREACH ACTIVITIES. THE CORPORATION DOES NOT ENGAGE IN ANY ACTIVITIES TO SUPPORT OR OPPOSE ANY CANDIDATE FOR PUBLIC OFFICE. PART II-B, LINE 1I, OTHER ACTIVITIES THE OTHER ACTIVITIES AMOUNT LISTED ON LINE 1I IS COMPRISED OF EXPENSES RELATED TO ORCHESTRATING CONTACT BETWEEN GRASSROOTS SUPPORTERS (WHO ARE VOLUNTEERS) AND ELECTED OFFICIALS TO PROMOTE THE INSTITUTION'S LEGISLATIVE OBJECTIVES. 26107905 26107905 569682098 253921856 315760242 3136748 3133146 3602 343603244 253061986 90541258 175651264 175651264 608064271 INTEREST IN NET ASSETS OF FOUNDATION 56393018 RECEIVABLES FROM CONTROLLED ORGS 5966358 OTHER RECEIVABLES 9340779 OTHER ASSETS 230000 RIGHT OF USE ASSET-OPERATING 47974232 119904387 LEASE OBLIGATIONS 35245938 OTHER LIABILITIES 539565 35785503 PART X, LINE 2 H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. DID NOT HAVE ANY UNCERTAIN POSITIONS IN ITS AUDITED FINANCIAL STATEMENTS, HOWEVER, THERE IS NO FOOTNOTE RELATING DIRECTLY TO UNCERTAIN TAX POSITIONS PRESENT IN THE STATEMENTS. THE ASC-740 FOOTNOTE READS AS FOLLOWS: THE CANCER CENTER RECORDS INCOME TAXES USING THE ASSET AND LIABILITY METHOD UNDER WHICH DEFERRED TAX ASSETS AND LIABILITIES ARE RECOGNIZED FOR EXPECTED FUTURE TAX CONSEQUENCES OF TEMPORARY DIFFERENCES BETWEEN FINANCIAL ACCOUNTING AND TAX BASES OF ASSETS AND LIABILITIES AND ARE MEASURED USING THE CURRENTLY ENACTED TAX RATE AND LAWS APPLICABLE IN THE PERIOD THAT THE DEFERRED TAX ASSET OR LIABILITY IS EXPECTED TO BE REALIZED OR SETTLED. 1 H LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE HOSPITAL INC 12902 MAGNOLIA DRIVE TAMPA FL 33612 593238634 501C3 49913 INTERCOMPANY SUPPORT M2GEN INC 10902 N MCKINLEY DRIVE TAMPA FL 33612 208486180 C CORP 22500 INTERCOMPANY SUPPORT TAMPA INNOVATON ALLIANCE INC 3100 E FLETCHER AVE TAMPA FL 33613 611692291 501C6 50000 SPONSORSHIP LEUKEMIA & LYMPHOMA SOCIETY 3505 E FRONTAGE RD STE 145 TAMPA FL 33607 135644916 501C3 40000 SPONSORSHIP NATIONAL PEDIATRIC CANCER 5550 W EXECUTIVE DR STE 200 TAMPA FL 33609 593097333 501C3 20000 SPONSORSHIP TAMPA ORG OF BLACK AFFAIRS 11266 W HILLSBOROUGH AVE STE 328 TAMPA FL 33635 592468415 501C4 15000 SPONSORSHIP DON'T EVER GIVE UP INC 14600 WESTON PKWY CARY NC 27513 475304184 501C3 12500 SPONSORSHIP AMERICAN CANCER SOCIETY INC 12810 USF MAGNOLIA DR TAMPA FL 33612 131788491 501C3 12500 SPONSORSHIP CDC OF TAMPA INC 1907 E HILLSBOROUGH AVE STE 100 TAMPA FL 33610 593150608 501C3 10000 SPONSORSHIP USF FOUNDATION 4202 E FOWLER AVE STOP ALC100 TAMPA FL 33620 590879015 501C3 10000 SPONSORSHIP METRO INCLUSIVE HEALTH 3251 3RD AVE N STE 125 ST PETERSBURG FL 33713 593153947 501C3 10000 SPONSORSHIP CURE ON WHEELS INC 200 2ND AVE S STE 475 ST PETERSBURG FL 33701 450568409 501C3 7500 SPONSORSHIP BIOFLORIDA INC 6742 FOREST HILL BLVD STE 256 WEST PALM BEACH FL 33413 593436638 501C6 7500 SPONSORSHIP LIONS EYE INSTITUTE FOUNDATION 1410 N 21ST ST TAMPA FL 33605 010843838 501C3 7000 SPONSORSHIP JACK & JILL OF AMERICA FOUND 1930 17TH STREET NW WASHINGTON DC 20009 204415512 501C3 6000 PLEDGE PAYMENT LIVE LIKE BELLA INC 2199 PONCE DE LEON BLVD STE 303 CORAL GABLES FL 33134 462965698 501C3 5600 SPONSORSHIP 12 4 PART I, LINE 2: THE SCHEDULE I, PART II, GRANTS LISTED AS SPONSORSHIPS ARE APPROVED THROUGH THE CHECK REQUEST PROCESS. BECAUSE OF THE NATURE OF THE GRANTS, THE GRANT USE IS NOT MONITORED SINCE THEY ARE GIVEN TO THE ORGANIZATION FOR A SPECIFIC PURPOSE OR EVENT. THE GRANTS LISTED AS INTERCOMPANY SUPPORT ARE ONLY MADE TO RELATED ORGANIZATIONS TO SUPPORT THEIR OPERATIONS. X 0 0 X X X X 1 1 0 0 0 1 1 0 0 JOHN A KOLOSKY EVP COO TO 1/4/2021 661191 0 240142 0 127292 0 734694 0 31131 0 1794450 0 0 0 YVETTE M LYONS TREMONTI EVP-CFAO & ASST TREASURER 677014 0 244811 0 125508 0 330785 0 35379 0 1413497 0 0 0 G DOUGLAS LETSON EVP-PIC 0 684196 0 249005 0 78138 0 178756 0 25325 0 1215420 0 0 L DAVID DE LA PARTE EVP GEN COUNS & ASST SEC 582568 0 212245 0 132973 0 255707 0 29911 0 1213404 0 0 0 JOHN CLEVELAND EVP-CENTER DIRECTOR 588133 0 182241 0 40895 0 150655 0 38497 0 1000421 0 0 0 JONATHAN ZAGER CHIEF ACADEMIC OFFICER 0 544539 0 143956 0 6212 0 191080 0 34689 0 920476 0 0 LYNN MOSCINSKI FRM CHIEF ACADEMIC OFFICER TO 6/28/2 0 528609 0 88528 0 16786 0 167493 0 22782 0 824198 0 0 JAMES J MULAY ACD TRANSLATIONAL RSCH 483881 0 132720 0 117922 0 30502 0 26568 0 791593 0 0 0 WJ WILSON VP GOVT RELATIONS 285686 0 88046 0 57889 0 313409 0 26791 0 771821 0 0 0 DANA E ROLLISON VP CHIEF DATA OFFICER 330308 0 95895 0 71425 0 195267 0 21655 0 714550 0 0 0 B LEE GREEN VP DIVERSITY, PR & STRAT COMM 320282 0 97449 0 69440 0 167012 0 31910 0 686093 0 0 0 EDMONDO ROBINSON SVP CHIEF DIGITAL INNOV OFFICER 539287 0 90491 0 11017 0 7113 0 33306 0 681214 0 0 0 ANNA GIULIANO DIRECTOR CENTER OF EXCELLENCE 366350 0 54679 0 8438 0 211771 0 35135 0 676373 0 0 0 BRIAN SPRINGER VP RESEARCH ADMINISTRATION 371842 0 108395 0 53698 0 99767 0 32096 0 665798 0 0 0 DIANE HAMMON VP CHIEF STRATEGY OFFICER 336839 0 102575 0 67097 0 115201 0 34433 0 656145 0 0 0 JOANNA WEISS VP FINANCE 328070 0 102856 0 56304 0 109791 0 37242 0 634263 0 0 0 SUSAN VADAPARAMPIL ACD COMMUNITY OUTREACH & ENGAGEMENT 308877 0 91330 0 52653 0 143285 0 22262 0 618407 0 0 0 MARIANA BUGALLO-MUROS VP CHIEF HR OFFICER 370857 0 112105 0 53049 0 38053 0 23765 0 597829 0 0 0 SHELLEY TWOROGER ACD POPULATION SCIENCE 323634 0 93615 0 35257 0 69894 0 15587 0 537987 0 0 0 ALAN F LIST FRM PRES/CEO TO 2/3/2020 136711 0 0 0 369936 0 24232 0 5397 0 536276 0 0 0 RANDA M PERKINS CHIEF MEDICAL INFO OFFICER 407998 0 54005 0 9558 0 41672 0 19959 0 533192 0 0 0 CHARLES FLETCHER VP DEPUTY GENERAL COUNSEL 282229 0 86947 0 36316 0 67039 0 36579 0 509110 0 0 0 DONALD FUTRELL VP PLAN, DESIGN & CONS 290046 0 89255 0 64941 0 30981 0 29562 0 504785 0 0 0 ROGER B BRADLEY VP FAC & SUP SVCS TO 10/15/2020 200483 9105 71961 0 53176 82 20644 0 9888 450 356152 9637 0 0 ELIZABETH LINDSAY-WOOD VP-CIO 261776 0 25000 0 5834 0 1834 0 2150 0 296594 0 0 0 PATRICK HWU PRES/CEO AS OF 11/10/2020 143847 0 0 0 75363 0 0 0 336 0 219546 0 0 0 HENRY REYES VP-PARTNERSHIP DEVELOPMENT 178557 0 15000 0 2160 0 718 0 14006 0 210441 0 0 0 SURESH D SERAPHIN FRM VP STRAT ALLIANCE & NETWK TO 5/1 65 0 0 0 112156 0 0 0 242 0 112463 0 0 0 THOMAS A SELLERS FRM EVP CNT DIR, DIR-MRI TO 2/3/2020 90130 0 0 0 158554 0 -149366 0 4182 0 103500 0 0 0 PART I, LINE 1A INSTITUTE PAYS MEMBERSHIP DUES TO A SOCIAL CLUB FOR DAVID DE LA PARTE AND W.J. WILSON. THE AMOUNT PAID IS SUBSEQUENTLY ADDED TO TAXABLE WAGES FOR THE RESPECTIVE INDIVIDUAL. PART I, LINE 1B: PAYMENTS MADE FOR SOCIAL CLUB DUES ARE INITIALLY APPROVED BY EXECUTIVE LEADERSHIP AND HUMAN RESOURCES AND REVIEWED/APPROVED BY THE JOINT EXECUTIVE COMPENSATION AND BENEFITS COMMITTEE (JE&BC), APPOINTED BY THE BOARD TO APPROVE SUCH PAYMENTS AND ASSOCIATED AMOUNTS. PART I, LINES 4A-B ROGER B. BRADLEY, VP FAC AND SUP SVC, AND SURESH D. SERAPHIN, FRM VP STRAT ALLIANCE & NETWK, RECEIVED SEVERENCE PAYMENTS TOTALING $32,309 AND $112,156, RESPECTIVELY, DURING THE FILING YEAR. TO BE ELIGIBLE TO PARTICIPATE IN THE 457(F) NON-QUALIFIED SUPPLEMENTAL EXECUTIVE RETIREMENT PLAN (SERP), PARTICIPANTS MUST ELECT TO CONTRIBUTE AT LEAST 10% ACROSS THE 403(B) AND 457(B) PLANS, AND ARE VESTED AFTER 10 YEARS OF SERVICE. LUMP SUM DISTRIBUTIONS FROM THE ACCOUNT ARE MADE UPON NORMAL RETIREMENT OR TERMINATION. BELOW ARE INDIVIDUALS LISTED ON MOFFITT'S 2020 FORM 990 PART VII, SECTION A, THAT PARTICIPATED IN THE 457(F) SUPPLEMENTAL EXECUTIVE RETIREMENT PLAN AND THEIR RESPECTIVE AMOUNTS OF COMPENSATION CONSTRUCTIVELY RECEIVED IN TAX YEAR 2020 FROM THE PLAN: G. DOUGLAS LETSON-$62,690 W. J. WILSON-$16,460 LOUIS D. DE LA PARTE-$48,525 DONALD E. FUTRELL-$18,251 JOHN A. KOLOSKY-$64,556 ALAN F. LIST-$213,192 YVETTE M. LYONS TREMONTI-$62,477 RANDA M. PERKINS-$8,857 JOANNA WEISS-$22,652 BERNARD L. GREEN-$19,591 DANA E. ROLLISON-$24,870 DIANE K. HAMMON-$22,395 SUSAN VADAPARAMPIL-$22,834 JAMES J. MULAY-$39,191 ANNA R. GIULIANO-$1,500 THOMAS A. SELLERS-$85,393 LYNN C. MOSCINSKI-$1,500 JONATHAN S. ZAGER-$4,500 MARIANA BUGALLO-MUROS-$0 JOHN L. CLEVELAND-$0 CHARLES R. FLETCHER-$0 BRIAN C. SPRINGER-$0 SHELLEY S. TWOROGER-$0 PART I, LINE 6 IN GENERAL, INCENTIVE COMPENSATION IS BASED ON A PERCENTAGE OF MOFFITT'S NET OPERATING INCOME AND ACHIEVEMENT AGAINST SPECIFIC ORGANIZATIONAL GOALS, DIVISIONAL AND/OR INDIVIDUAL GOALS, PROVIDED A CERTAIN NET OPERATING INCOME THRESHOLD IS MET. SCHEDULE J COLUMN C: THE NEGATIVE AMOUNT SHOWN FOR THOMAS SELLERS IS A DECREASE IN ACTUARIAL VALUE OF THE DEFINED BENEFIT PLAN INCLUDED IN RETIREMENT AND OTHER DEFERRED COMPENSATION. A HILLSBOROUGH CTY INDUSTRIAL DEV AUTHORITY 591293512 NONEAVAIL 2015-10-06 9750000 SEE SUPPLEMENTAL SCH K PART VI 0 0 0 B HILLSBOROUGH CTY INDUSTRIAL DEV AUTHORITY 591293512 NONEAVAIL 2015-10-22 8690000 SEE SUPPLEMENTAL SCH K PART VI 0 0 0 C CITY OF TAMPA 591101138 875282BE4 2012-09-19 144692131 SEE SUPPLEMENTAL SCH K PART VI 0 0 0 D CITY OF TAMPA 591101138 875161BN0 2012-11-29 39972900 SEE SUPPLEMENTAL SCH K PART VI 0 0 0 A 1120000 9774742 8652677 1122065 2010 1 0 1 1 B 4610000 8712052 7711975 1000077 2010 1 0 1 1 C 34500000 146142503 17913907 1176163 126534872 514657 2904 2016 1 0 1 1 D 13485000 40685437 40400552 284885 2012 1 0 1 1 A 0 1 1 1 0 0 0 1 B 0 1 1 1 0 0 0 1 C 0 1 1 1 0 0 0 1 A 0 0 0 1 1 0 0 0 1 B 0 0 0 1 1 0 0 0 1 C 0 1 0 1 0 0 0 0 1 D 0 1 0 1 0 0 0 0 1 A 1 B 1 C 1 D 1 DATE REBATE COMPUTATION PERFORMED ISSUER NAME: HILLSBOROUGH CTY INDUSTRIAL DEV AUTHORITY DATE THE REBATE COMPUTATION WAS PERFORMED: 09/01/2020 ISSUER NAME: HILLSBOROUGH CTY INDUSTRIAL DEV AUTHORITY DATE THE REBATE COMPUTATION WAS PERFORMED: 09/01/2020 FORM 990, SCHEDULE K, PART IA COLUMN (F) REPLACEMENT BONDS 2015A WERE ISSUED FOR A PORTION OF THE OUTSTANDING PRINCIPAL BALANCE OF THE 2010A SERIES AND USED FOR: 1)RETIRING A PORTION OF THE 2010A BOND. 2)FINANCING AND REFINANCING CERTAIN OTHER CAPITAL COSTS PREVIOUSLY INCURRED BY THE HOSPITAL WITH RESPECT TO SUCH PROJECTS. FORM 990, SCHEDULE K, PART IB COLUMN (F) REPLACEMENT BONDS 2015B WERE ISSUED FOR A PORTION OF THE OUTSTANDING PRINCIPAL BALANCE OF THE 2010A SERIES AND USED FOR: 1)RETIRING A PORTION OF THE 2010A BOND. 2)FINANCING AND REFINANCING CERTAIN OTHER CAPITAL COSTS PREVIOUSLY INCURRED BY THE HOSPITAL WITH RESPECT TO SUCH PROJECTS. FORM 990, SCHEDULE K, PART IC COLUMN (F) PROCEEDS FROM THE 2012A BONDS WERE USED FOR: 1) ACQUISITION, CONSTRUCTION, FURNISHING AND EQUIPPING OF THE MULTI-STORY MCKINLEY CLINICAL RESEARCH FACILITY AND INFRASTRUCTURE THAT WILL CONTAIN AN AMBULATORY SURGERY CENTER, PROCEDURE SUITES, CLINICS, IMAGING, INFUSION, SCREENING AND DRY LAB RESEARCH. 2)CONSTRUCTION, RENOVATION, AND EQUIPPING CLINICAL AND RESEARCH FACILITIES INCLUDING ADDITIONAL BED CAPACITY, OPERATING SUITES AND ASSOCIATED FACILITIES AND INFRASTRUCTURE. 3) A PORTION OF THE 2012A PROCEEDS WAS USED TO CURRENT REFUND 2002A AND 2002B SERIES BONDS, BOTH ISSUED NOVEMBER 14, 2002. FORM 990, SCHEDULE K, PART ID COLUMN (F) 1) SERIES 2012B WERE PROCEEDS USED TO CURRENT REFUND SERIES 1999A AND 2002C BONDS, ISSUED MARCH 25, 1999 AND NOVEMBER 14, 2002 RESPECTIVELY. FORM 990, SCHEDULE K, PART IE COLUMN (F) PROCEEDS OF THE 2016A BOND ISSUANCE WERE USED TO PURCHASE LAND AND BUILDING ON USF CAMPUS AND AN ADDITIONAL MCKINLEY CAMPUS SITE FOR CONSTRUCTION OF RESEARCH AND RESEARCH SUPPORT FACILITIES, CLINICAL AND RESEARCH SUPPORT OFFICES, THE RELOCATION OF CHILD DEVELOPMENT CENTER, AND THE CONSTRUCTION OF RESEARCH LABS. FORM 990, SCHEDULE K, PART IF COLUMN (F) SERIES 2016B IS AN ADVANCE REFUNDING ON SERIES 2007A WHICH WAS USED TO: 1) FINANCE THE COST OF CONSTRUCTION AND EQUIPPING A FOUR STORY ADDITION TO THE MAIN CAMPUS OF THE HOSPITAL, TO INCLUDE 36 ADDITIONAL INPATIENT BEDS, RADIATION ONCOLOGY CLINIC PROGRAM EXPANSION WITH THE ADDITION OF TWO NEW VAULTS USED FOR STATE OF THE ART LINEAR ACCELERATORS, CLINICAL LAB AND PATHOLGY PROGRAM EXPANSION, APPROXIMATELY 40,000 GROSS SQUARE FEET OF FACULTY OFFICE SPACE, AND 1,000 SPACE PARKING GARAGE. 2) FINANCE THE COST OF VARIOUS BACKFILL AND REFURBISHMENT PROJECTS, INCLUDING THE ADDITION OF EIGHT INPATIENT BEDS IN EXISTING SPACE LOCATED AT THE INSTITUTE AND HOSPITAL. FORM 990, SCHEDULE K, PART IG COLUMN (F) PROCEEDS FROM THE 2020A (IN ADDITION TO THE 2020B) BONDS WILL BE USED FOR: 1) ACQUISITION, CONSTRUCTION, FURNISHING AND EQUIPPING OF VARIOUS MEDICAL AND RESEARCH FACILITIES CAPITAL PROJECTS INCLUDING HOSPITAL EXPANSION PROJECT. 2)VARIOUS FACILITIES, INFRASTRUCTURE SUPPORT, EQUIPMENT, FURNISHINGS, BACKFILL AND REFURBISHMENT PROJECTS. FORM 990, SCHEDULE K, PART IH COLUMN (F) PROCEEDS FROM THE 2020B (IN ADDITION TO 2020A) BONDS WILL BE USED FOR: 1) ACQUISITION, CONSTRUCTION, FURNISHING AND EQUIPPING OF VARIOUS MEDICAL AND RESEARCH FACILITIES CAPITAL PROJECTS INCLUDING HOSPITAL EXPANSION PROJECT. 2)VARIOUS FACILITIES, INFRASTRUCTURE SUPPORT, EQUIPMENT, FURNISHINGS, BACKFILL AND REFURBISHMENT PROJECTS. FORM 990, SCHEDULE K PART II THE DIFFERENCE BETWEEN ISSUE PRICE IN SCHEDULE K, PART I AND TOTAL PROCEEDS OF THE ISSUE IN PART II, LINE 2 FOR EACH ISSUE IS INVESTMENT EARNINGS WITH THE EXCEPTION OF THE 2012A SERIES WHICH INCLUDES THE ADDITION OF SINKING FUNDS IN THE AMOUNT OF $709,282 FROM THE SERIES 2002A AND 2002B. A CITY OF TAMPA 591101138 875146AQ5 2016-11-16 58742390 SEE SUPPLEMENTAL SCH K PART VI 0 0 0 B CITY OF TAMPA 591101138 875161CE9 2016-11-03 93832926 SEE SUPPLEMENTAL SCH K PART VI 0 0 0 C CITY OF TAMPA 591101138 875146BD3 2020-06-25 119978935 SEE SUPPLEMENTAL SCH K PART VI 0 0 0 D CITY OF TAMPA 591101138 875161DD0 2020-06-25 302148464 SEE SUPPLEMENTAL SCH K PART VI 0 0 0 A 7225000 60760499 594871 58147019 18519 2000090 2019 0 0 1 1 B 8175000 93840309 92779020 1061289 2010 1 0 1 1 C 120211331 1084744 36723911 82402676 0 0 0 1 D 302927256 1882947 65859131 235185178 0 0 0 1 A 0 0 0 0 0 0 1 B 0 0 0 0 0 0 1 C 0 0 0 0 0 0 1 D 0 0 0 0 0 0 1 A 0 1 0 1 0 0 0 0 1 B 0 1 0 1 0 0 0 0 1 C 0 1 0 1 0 0 1 THE TORONTO DOMINION BANK 1.750000000000 1 0 1 D 0 1 0 1 0 0 1 THE TORONTO DOMINION BANK 1.750000000000 1 0 1 A 1 B 1 C 1 D 1 X EQUIPMENT 23 946452 PURCHASE PRICE 0 0 0 0 PART I, COLUMN (B): THE NUMBER ON LINE 25(B) REPRESENTS THE NUMBER OF CONTRIBUTIONS, NOT THE NUMBER OF ITEMS CONTRIBUTED. FORM 990, PART VI, SECTION A, LINE 2 THE FOLLOWING DIRECTORS AND OFFICERS, THAT JOINTLY SERVE ON THE INSTITUTE AND A FOR-PROFIT RELATED ENTITY, QUALIFY AS HAVING A BUSINESS RELATIONSHIP. INSTITUTE & MOFFITT GENETICS CORPORATION (M2GEN): TIMOTHY J. ADAMS, INSTITUTE DIRECTOR & M2GEN DIRECTOR EDMONDO ROBINSON, INSTITUTE OFFICER & M2GEN DIRECTOR LOUIS D. DE LA PARTE, INSTITUTE OFFICER & M2GEN OFFICER YVETTE M. LYONS TREMONTI, INSTITUTE OFFICER & M2GEN OFFICER INSTITUTE & MOFFITT TECHNOLOGIES CORPORATION (MTC): JOHN A. KOLOSKY, OFFICER INSTITUTE & MTC DIRECTOR LOUIS D. DE LA PARTE, OFFICER INSTITUTE & MTC OFFICER YVETTE M. LYONS TREMONTI, OFFICER INSTITUTE & MTC OFFICER PATRICK HWU, OFFICER INSTITUTE & MTC DIRECTOR INSTITUTE & ONCOBAY CLINICAL (ONCOBAY): GEOFFREY M. DUYK, INSTITUTE DIRECTOR & ONCOBAY DIRECTOR LOUIS D. DE LA PARTE, INSTITUTE OFFICER & ONCOBAY DIRECTOR YVETTE M. LYONS TREMONTI, INSTITUTE OFFICER & ONCOBAY DIRECTOR FORM 990, PART VI, SECTION B, LINE 11B PRIOR TO ELECTRONICALLY FILING FORM 990 (RETURN OF ORGANIZATION EXEMPT FROM INCOME TAX), A COPY OF THE RETURN IS PROVIDED TO THE GOVERNING BODY, GIVING EACH BOARD MEMBER TIME TO REVIEW THE RETURN. BOARD MEMBERS HAVE THE OPPORTUNITY TO ASK QUESTIONS RELATED TO THE INFORMATION PROVIDED ON THE RETURN. MOFFITT'S FORM 990 IS ALSO PROVIDED TO THE CHIEF FINANCIAL OFFICER FOR REVIEW. BASED ON THE REVIEW ANY SUGGESTED COMMENTS OR CHANGES ARE DISCUSSED PRIOR TO SIGNING. FORM 990, PART VI, SECTION B, LINE 12C ON AN ANNUAL BASIS A PRESENTATION IS MADE TO RESEARCH BOARD MEMBERS TO REVIEW THE CONFLICT OF INTEREST POLICY AND PROCEDURES FOR DISCLOSING ANY POTENTIAL CONFLICTS. EACH DIRECTOR, OFFICER, COMMITTEE MEMBER, AND KEY EMPLOYEE SHALL COMPLETE A CONFLICT OF INTEREST DISCLOSURE CERTIFICATION VIA THE ELECTRONIC DISCLOSURE SYSTEM. ANY DIRECTOR, OFFICER, COMMITTEE MEMBER, OR KEY EMPLOYEE WHO REASONABLY BELIEVES THAT HE OR SHE MAY HAVE AN ACTUAL OR POTENTIAL CONFLICT OF INTEREST MUST DISCLOSE THE EXISTENCE OF AND THE MATERIAL FACTS OF THE NATURE OF HIS/HER INTEREST ON THE FORM. THE ELECTRONIC FORM IS SUBMITTED TO THE CORPORATE COMPLIANCE OFFICE, WHICH REVIEWS THE FORMS, GATHERS ADDITIONAL RELEVANT INFORMATION WHERE NECESSARY, AND PREPARES A SUMMARY OF THE DISCLOSURES TO BE REVIEWED BY THE CONFLICT OF INTEREST WORK GROUP. IF A DIRECTOR OR COMMITTEE MEMBER DISCLOSES THAT HE/SHE HAS A POTENTIAL CONFLICT OF INTEREST AT A BOARD OR COMMITTEE MEETING, SUCH DIRECTOR OR COMMITTEE MEMBER MUST DISCLOSE THE NATURE OF THE INTEREST AND ANY RELATED INFORMATION AND RESPOND TO QUESTIONS AS MAY BE REQUIRED BY THE REMAINING MEMBERS. BASED ON THE INFORMATION DISCLOSED, THE REMAINING BOARD MEMBERS WILL DETERMINE WHETHER A CONFLICT OF INTEREST EXISTS. IF A CONFLICT EXISTS THE BOARD OR COMMITTEE SHALL DETERMINE WHETHER AN ALTERNATIVE TRANSACTION OR ARRANGEMENT THAT WOULD NOT GIVE RISE TO A CONFLICT IS EQUALLY ADVANTAGEOUS. IF AN ALTERNATIVE TRANSACTION IS NOT EQUALLY ADVANTAGEOUS THE DIRECTOR OR COMMITTEE MEMBER WHO IS THE SUBJECT OF THE CONFLICT SHALL NOT VOTE ON, NOR USE HIS/HER PERSONAL INFLUENCE ON, NOR PARTICIPATE IN DISCUSSIONS OR DELIBERATIONS WITH RESPECT TO THE TRANSACTION. FORM 990, PART VI, SECTION B, LINE 15 MOFFITT'S BOARD OF DIRECTORS HAS AN ESTABLISHED SUB-COMMITTEE, THE JOINT EXECUTIVE COMPENSATION & BENEFITS COMMITTEE (JEC&BC) THAT IS MADE UP ENTIRELY OF INDEPENDENT, OUTSIDE DIRECTORS. THIS COMMITTEE IS CHARGED WITH THE OVERSIGHT OF THE PERFORMANCE AND COMPENSATION OF MOFFITT EXECUTIVES AND DISQUALIFIED PERSONS. THESE POSITIONS INCLUDE THE CEO, EXECUTIVE VICE PRESIDENTS, SENIOR VICE PRESIDENTS, VICE PRESIDENTS AND DEPARTMENT CHAIRPERSONS. TO ACCOMPLISH ITS MISSION, THE COMMITTEE CAN AS NEEDED AND DOES AT ITS DISCRETION, ENGAGE INDEPENDENT, OUTSIDE ADVISORS INCLUDING, BUT NOT LIMITED TO ATTORNEYS AND COMPENSATION CONSULTANTS. ON AN ANNUAL BASIS THE JEC&BC ENGAGES A NATIONALLY KNOWN, THIRD PARTY CONSULTING FIRM TO PROVIDE A DETAILED STUDY OF THE CASH COMPENSATION FOR EACH EXECUTIVE, DISQUALIFIED PERSON AND INDIVIDUAL IN KEY POSITIONS. THE CONSULTANT USES A VARIETY OF PUBLISHED SURVEYS COMPILED BY INDEPENDENT FIRMS TO PROVIDE THE SOURCE DATA FOR THE STUDY. USING FUNCTIONALLY COMPARABLE POSITIONS IN OTHER SIMILARLY SIZED, NOT-FOR-PROFIT AND FOR-PROFIT HEALTHCARE, ACADEMIC AND RESEARCH ORGANIZATIONS, THE CONSULTING FIRM PRODUCES A STUDY THAT COMPARES EACH DESIGNATED MOFFITT POSITION TO ITS APPROPRIATE MARKET EQUIVALENT. THE RESULTING DATA IS PROVIDED TO THE DIRECTOR OF COMPENSATION, WHO IS NOT INCLUDED IN THE EXECUTIVE OR DISQUALIFIED PERSON CATEGORIES, FOR USE IN THE FORMULATION OF RECOMMENDATIONS FOR COMPENSATION CHANGES TO MAINTAIN MARKET COMPETITIVENESS OR TO REWARD PERFORMANCE. THESE RECOMMENDATIONS ALONG WITH THE CONSULTANT'S COMPARABILITY DATA ARE PRESENTED TO THE JEC&BC FOR IT TO CONFIRM ITS REASONABLENESS, MAKE MODIFICATIONS AS IT DEEMS NECESSARY AND PROVIDE FINAL APPROVAL. EVERY THIRD YEAR THE INDEPENDENT CONSULTANT ANALYZES THE TOTAL EXECUTIVE COMPENSATION PROGRAM, USING THE SAME METHODOLOGY AS DESCRIBED ABOVE, THAT INCLUDES THE VALUE OF ALL BENEFITS AND PERQUISITES (CASH AND NON-CASH) PROVIDED AS COMPENSATION TO THE EXECUTIVES AND DISQUALIFIED PERSONS. THE PURPOSE OF THE ANALYSIS IS TO PROVIDE AN OPINION ON THE REASONABLENESS OF EACH OF THE INDIVIDUAL COMPENSATION COMPONENTS AND THE AGGREGATE COMPENSATION TOTAL. THIS MORE COMPREHENSIVE ANALYSIS IS PROVIDED TO THE JEC&BC FOR THEIR USE IN THE ANNUAL REVIEW PROCESS. MINUTES ARE KEPT AT EACH OF THESE ANNUAL MEETINGS DETAILING THE RECOMMENDATIONS PRESENTED AND THE DECISIONS MADE BY THE COMMITTEE. THESE MINUTES ARE PUBLISHED TO THE COMMITTEE AT THE NEXT MEETING AND REPORTED TO THE BOARD. FORM 990, PART VI, SECTION C, LINE 19 MOFFITT RESEARCH MAKES AVAILABLE TO THE PUBLIC THROUGH DAC BOND, THIRD PARTY VENDORS' WEBSITE AND MOFFITT'S WEBSITE THE CONSOLIDATED AUDITED FINANCIAL STATEMENTS. IN ADDITION FORM 990 IS MADE AVAILABLE ON GUIDESTAR AS WELL AS ON MOFFITT'S WEBSITE. ALL ORGANIZING AND GOVERNING DOCUMENTS SUCH AS FORM 1023, CONFLICTS OF INTEREST POLICY, AND BYLAWS AS WELL AS FORM 990 AND AUDITED FINANCIAL STATEMENTS ARE MADE AVAILABLE UPON REQUEST. FORM 990, PART VI, SECTION B, LINE 16B: THE ORGANIZATION HAS ADOPTED A WRITTEN JOINT VENTURE PROCEDURE WITH WHICH IT COMPLIES. IN MARCH 2021, MOFFITT ENTERED INTO A LIMITED PARTNERSHIP AGREEMENT WITH CERTAIN INVESTORS TO FORM M2GEN HOLDINGS, L.P. WHERE THE CANCER CENTER'S OUTSTANDING EQUITY INTEREST IN M2GEN, CORP. WAS EXCHANGED FOR A PARTNERSHIP INTEREST IN M2GEN HOLDINGS, L.P. THE CANCER CENTER OWNS 4,375 PARTNERSHIP UNITS IN THE NEWLY FORMED M2GEN HOLDINGS, L.P. (WHICH IS APPROXIMATELY 18.6% OF OUTSTANDING PARTNERSHIP UNITS). THE CANCER CENTER DOES NOT HAVE THE ABILITY TO EXERCISE SIGNIFICANT INFLUENCE OVER THE OPERATING AND FINANCIAL DECISIONS OF M2GEN HOLDINGS, L.P. M2GEN OPERATIONS INVOLVE ONCOLOGY-FOCUSED HEALTH INFORMATICS SOLUTIONS WITH THE MISSION TO HELP PATIENTS GET ACCESS TO THE BEST TREATMENTS BY LEVERAGING CLINICAL AND MOLECULAR DATA TO TAILOR PERSONALIZED THERAPIES. ON AN ONGOING BASIS, FOR NEW AND EXISTING ARRANGEMENTS SUCH AS THIS, MOFFITT FOLLOWS PROCEDURES THAT REQUIRE THE EVALUATION OF ITS PARTICIPATION IN THESE ARRANGMENTS AND TAKES ANY NECESSARY STEPS TO SAFEGUARD ITS EXEMPT STATUS. FORM 990, PART IX, LINE 11G CONSULTING SERVICES: PROGRAM SERVICE EXPENSES 851,291. MANAGEMENT AND GENERAL EXPENSES 2,840,292. FUNDRAISING EXPENSES 0. TOTAL EXPENSES 3,691,583. PURCHASED SERVICES: PROGRAM SERVICE EXPENSES 10,997,578. MANAGEMENT AND GENERAL EXPENSES 15,132,265. FUNDRAISING EXPENSES 0. TOTAL EXPENSES 26,129,843. SUBCONTRACTS: PROGRAM SERVICE EXPENSES 5,251,107. MANAGEMENT AND GENERAL EXPENSES 0. FUNDRAISING EXPENSES 0. TOTAL EXPENSES 5,251,107. FORM 990, PART IX, COLUMN (D): THERE ARE NO FUNDRAISING EXPENSES BECAUSE H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE FOUNDATION, INC. HANDLES ALL FUNDRAISING ACTIVITIES FOR H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. AND ITS SUBSIDIARIES. FORM 990, PART IX, LINE 24A CERTAIN MOFFITT CANCER CENTER INTERCOMPANY OVERHEAD HAS BEEN ALLOCATED FROM THE PARENT ENTITY TO THE SUBSIDARY ENTITIES AND THOSE AMOUNTS ARE INCLUDED IN COLUMN (C) AND THEN REALLOCATED ON LINE 24A TO THE PROPER FUNCTIONAL CATEGORIES. FORM 990, PART XI, LINE 9: CHANGES IN NET ASSETS PREDOMINANTLY RELATES TO THE CLOSE OUT OF INTERCOMPANY ACCOUNTS PAYABLE AND RECEIVABLES (DUE TO/DUE FROM) IN THE AMOUNT OF $185,951,423 TO NET ASSETS AND DECONSOLIDATION ADJUSTMENT UPON SALE OF M2GEN $36,266,762. H LEE MOFFITT CANCER CTR & RESEARCH INSTITUTE HOSPITAL INC 12902 MAGN0LIA DRIVE TAMPA FL 33612 593238634 PATIENT CARE FL 501(C)(3) LINE 3 H LEE MOFFITT CANCER CTR & RES INST INC 1 H LEE MOFFITT CANCER CTR & RESEARCH INSTITUTE FOUNDATION INC 12902 MAGN0LIA DRIVE TAMPA FL 33612 593238636 FUNDRAISING FL 501(C)(3) LINE 7 H LEE MOFFITT CANCER CTR & RES INST INC 1 H LEE MOFFITT CC&RI LIFETIME CANCER SCREENING CENTER INC 12902 MAGN0LIA DRIVE TAMPA FL 33612 593238640 PRACTICE MANAGEMENT FL 501(C)(3) LINE 10 H LEE MOFFITT CANCER CTR & RES INST INC 1 MOFFITT TECHNOLOGIES CORPORATION 12902 MAGNOLIA DRIVE TAMPA FL 33612 300332914 TECHNOLOGY MANAGEMENT FL H LEE MOFFITT CC&RI INC C -1620 264307 1.00000 1 M2GEN CORP 10902 N MCKINLEY DRIVE TAMPA FL 33612 208486180 DATABASE MANAGEMENT FL H LEE MOFFITT CC&RI INC C -5743335 0.67300 1 ONCOBAY CLINICAL INC 10902 N MCKINLEY DRIVE TAMPA FL 33612 843412796 RESEARCH & PRODUCT DEVELOPMENT FL H LEE MOFFITT CC&RI INC C -2715225 8119316 1.00000 1 1 1 1 0 0 0 0 0 0 0 0 1 1 1 0 1 1 0 1 M2GEN CORP B 22500 FMV H LEE MOFFITT CC&RI HOSPITAL INC B 49913 FMV H LEE MOFFITT CC&RI HOSPITAL INC C 10576932 FMV H LEE MOFFITT CC&RI FOUNDATION INC C 11548309 FMV M2GEN CORP S 955503 FMV H LEE MOFFITT CC&RI FOUNDATION INC Q 6192060 FMV M2GEN CORP Q 816646 FMV M2GEN CORP L 1927290 FMV ONCOBAY CLINICAL INC P 20231 FMV ONCOBAY CLINICAL INC A 7800 FMV ONCOBAY CLINICAL INC A 146314 FMV